University Hospital Tuebingen

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Private

Established: 1388-01-01

Employees: -

Market Cap: -

Website: https://www.klinikum.uni-heidelberg.de/Startseite.2.0.html?&no_cache=1

Clinical Trials

Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Non-Hodgkin Lymphoma

First Posted Date: 2006-03-14

Last Posted Date: 2014-05-29

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 60

Registration Number: NCT00302757

Locations: 🇩🇪
Medical Center Charite Benjamin Franklin, Berlin, Germany
🇩🇪
University of Dresden Medical Center, Dresden, Germany
🇩🇪
South West German Cancer Center, University of Tuebingen Medical Center, Tuebingen, Germany

and more 8 locations

Study With Mitomycin c/5-FU/FA in Pretreated Gastrointestinal Cancer Patients With Metastases (>= Second-line Treatment)

Phase 1

Completed

Conditions: Gastrointestinal Neoplasms
Neoplasm Metastasis

First Posted Date: 2006-02-09

Last Posted Date: 2013-01-28

Lead Sponsor: University Hospital Tuebingen

Registration Number: NCT00289445

Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)

Phase 2

Completed

Conditions: Dysgerminoma

First Posted Date: 2005-09-20

Last Posted Date: 2009-02-16

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 108

Registration Number: NCT00204633

Locations: 🇩🇪
Medical Center II, University of Tuebingen, Tuebingen, Germany

Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)

Phase 2

Completed

Conditions: Sarcoma, Soft Tissue

First Posted Date: 2005-09-20

Last Posted Date: 2007-04-20

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 28

Registration Number: NCT00204620

Locations: 🇩🇪
Medical center II, University of Tuebingen, Tuebingen, Germany

Neoadjuvant Adriamycin and Ifosfamide Plus High-Dose ICE in Patients With Soft Tissue Sarcoma (STS)

Phase 2

Completed

Conditions: Sarcoma, Soft Tissue

First Posted Date: 2005-09-20

Last Posted Date: 2007-04-20

Lead Sponsor: University Hospital Tuebingen

Registration Number: NCT00204646

Locations: 🇩🇪
Medical Center II, University of Tuebingen, Tuebingen, Germany

Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients

Phase 1

Completed

Conditions: Malignant Melanoma

First Posted Date: 2005-09-20

Last Posted Date: 2007-04-19

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 20

Registration Number: NCT00204607

Locations: 🇩🇪
Department of Dermatology, University of Tübingen, Tübingen, Germany

Time of Ventilation and Lung Function of Ventilated Patients Under Therapy With Dornase Alfa

Phase 2

Conditions: Long Term Ventilation

First Posted Date: 2005-09-20

Last Posted Date: 2006-09-14

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 540

Registration Number: NCT00204685

Locations: 🇩🇪
Charité, Universitätsmedizin Berlin, Campus Mitte, Innere Intensivstation, Berlin, Germany
🇩🇪
Universität Charité, Campus Mitte, Anästhesie, Intensivstation, Berlin, Germany
🇩🇪
Universitätsklinikum Erlangen Medizinische Klinik, Intensivstation I, Erlangen, Germany

and more 22 locations

Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28

Phase 1

Completed

Conditions: Malignant Melanoma

Interventions: Drug: rM28
Drug: autologous PBMCs

First Posted Date: 2005-09-20

Last Posted Date: 2013-01-16

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 1

Registration Number: NCT00204594

Locations: 🇩🇪
University of Tuebingen, Department of dermatology, Tuebingen, Germany

Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens

Phase 1

Completed

Conditions: Malignant Melanoma

Interventions: Biological: mRNA coding for melanoma associated antigens
Drug: GM-CSF

First Posted Date: 2005-09-20

Last Posted Date: 2013-01-16

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 31

Registration Number: NCT00204516

Locations: 🇩🇪
Department of Dermatology, University of Tuebingen, Tuebingen, Germany

Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma

Phase 4

Completed

Conditions: Carcinoma, Basal Cell

First Posted Date: 2005-09-20

Last Posted Date: 2011-09-01

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 100

Registration Number: NCT00204555

Locations: 🇩🇪
Skin Cancer Program, Department of Dermatology, Liebermeisterstrasse 8, Tübingen, BW, Germany

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy